Metered dose inhaler induced bronchospasm in asthmatic patients.
Beta-adrenergic agonists in metered dose inhalers (MDIs) are used extensively in the treatment of asthma. Previously we reported that 23 of 1450 (1.6%) of our asthmatic patients experienced immediate bronchoconstriction after using MDI-albuterol. In this study we investigated immediate bronchoconstriction after use of MDI-metaproterenol and after placebo-inhaler with "inert ingredients" only. Results suggest that those patients who complained of chest tightness or lack of relief following the use of MDI beta-adrenergic agonists are having true bronchoconstriction. The bronchoconstrictive response is most likely caused by the propellants or the other inert ingredients contained in these MDIs.
D000281:Administration, Intranasal / Q000009:adverse effects*; D000335:Aerosol Propellants / Q000009:adverse effects*; D000336:Aerosols / Q000009:adverse effects*; D001249:Asthma / Q000188:drug therapy* / Q000503:physiopathology; D001986:Bronchial Spasm / Q000139:chemically induced* / Q000503:physiopathology; D005541:Forced Expiratory Volume; D006801:Humans; D009921:Metaproterenol / Q000627:therapeutic use
D000335:Aerosol Propellants; D000336:Aerosols; D009921:Metaproterenol